Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study

Andrea Z. LaCroix, Jane A. Cauley, Mary Pettinger, Judith Hsia, Douglas C. Bauer, Joan McGowan, Zhao Chen, Cora E. Lewis, S. Gene McNeeley, Maureen D. Passaro, Rebecca D. Jackson

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results. Objective: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density. Design: Prospective study. Setting: Women's Health Initiative Observational Study conducted in 40 clinical centers in the United States. Participants: 93 716 postmenopausal women ages 50 to 79 years. Measurements: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use. Results: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivariate-adjusted hazard ratios for current statin use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors. Conclusion: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.

Original languageEnglish (US)
Pages (from-to)97-104+I27
JournalAnnals of Internal Medicine
Volume139
Issue number2
StatePublished - Jul 15 2003
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Women's Health
Bone Density
Observational Studies
Wrist
Hip
Arm
Hip Fractures
Osteogenesis
Osteoporosis
Epidemiologic Studies
Oxidoreductases
Spine
Body Mass Index
X-Rays

ASJC Scopus subject areas

  • Medicine(all)

Cite this

LaCroix, A. Z., Cauley, J. A., Pettinger, M., Hsia, J., Bauer, D. C., McGowan, J., ... Jackson, R. D. (2003). Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study. Annals of Internal Medicine, 139(2), 97-104+I27.

Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women : Results from the Women's Health Initiative Observational Study. / LaCroix, Andrea Z.; Cauley, Jane A.; Pettinger, Mary; Hsia, Judith; Bauer, Douglas C.; McGowan, Joan; Chen, Zhao; Lewis, Cora E.; McNeeley, S. Gene; Passaro, Maureen D.; Jackson, Rebecca D.

In: Annals of Internal Medicine, Vol. 139, No. 2, 15.07.2003, p. 97-104+I27.

Research output: Contribution to journalArticle

LaCroix, AZ, Cauley, JA, Pettinger, M, Hsia, J, Bauer, DC, McGowan, J, Chen, Z, Lewis, CE, McNeeley, SG, Passaro, MD & Jackson, RD 2003, 'Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study', Annals of Internal Medicine, vol. 139, no. 2, pp. 97-104+I27.
LaCroix, Andrea Z. ; Cauley, Jane A. ; Pettinger, Mary ; Hsia, Judith ; Bauer, Douglas C. ; McGowan, Joan ; Chen, Zhao ; Lewis, Cora E. ; McNeeley, S. Gene ; Passaro, Maureen D. ; Jackson, Rebecca D. / Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women : Results from the Women's Health Initiative Observational Study. In: Annals of Internal Medicine. 2003 ; Vol. 139, No. 2. pp. 97-104+I27.
@article{a4d8342011a44baead9cd84405fcae09,
title = "Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study",
abstract = "Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results. Objective: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density. Design: Prospective study. Setting: Women's Health Initiative Observational Study conducted in 40 clinical centers in the United States. Participants: 93 716 postmenopausal women ages 50 to 79 years. Measurements: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use. Results: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivariate-adjusted hazard ratios for current statin use were 1.22 (95{\%} CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors. Conclusion: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.",
author = "LaCroix, {Andrea Z.} and Cauley, {Jane A.} and Mary Pettinger and Judith Hsia and Bauer, {Douglas C.} and Joan McGowan and Zhao Chen and Lewis, {Cora E.} and McNeeley, {S. Gene} and Passaro, {Maureen D.} and Jackson, {Rebecca D.}",
year = "2003",
month = "7",
day = "15",
language = "English (US)",
volume = "139",
pages = "97--104+I27",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women

T2 - Results from the Women's Health Initiative Observational Study

AU - LaCroix, Andrea Z.

AU - Cauley, Jane A.

AU - Pettinger, Mary

AU - Hsia, Judith

AU - Bauer, Douglas C.

AU - McGowan, Joan

AU - Chen, Zhao

AU - Lewis, Cora E.

AU - McNeeley, S. Gene

AU - Passaro, Maureen D.

AU - Jackson, Rebecca D.

PY - 2003/7/15

Y1 - 2003/7/15

N2 - Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results. Objective: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density. Design: Prospective study. Setting: Women's Health Initiative Observational Study conducted in 40 clinical centers in the United States. Participants: 93 716 postmenopausal women ages 50 to 79 years. Measurements: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use. Results: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivariate-adjusted hazard ratios for current statin use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors. Conclusion: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.

AB - Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results. Objective: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density. Design: Prospective study. Setting: Women's Health Initiative Observational Study conducted in 40 clinical centers in the United States. Participants: 93 716 postmenopausal women ages 50 to 79 years. Measurements: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use. Results: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivariate-adjusted hazard ratios for current statin use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors. Conclusion: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=1642461391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642461391&partnerID=8YFLogxK

M3 - Article

C2 - 12859159

AN - SCOPUS:1642461391

VL - 139

SP - 97-104+I27

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -